Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217667 | 0.83 | CCNA2 (0.32) | TRPV1TAAR1 | |
| SCHEMBL5215713 | 0.79 | ALDH1A1 (0.34) | TRPV1ALDH1A1 | |
| SCHEMBL5215320 | 0.78 | TAAR1 (0.35) | TAAR1KMT2A | |
| SCHEMBL5218572 | 0.72 | ERBB2 (0.33) | — | |
| SCHEMBL14422197 | 0.70 | TRPV1 (0.47) | TRPV1RAB9AABL1KMT2A | |
| SCHEMBL5221352 | 0.65 | TRPV1 (0.44) | TRPV1 | |
| SCHEMBL5219282 | 0.64 | TRPV1 (0.41) | TRPV1 | |
| SCHEMBL5219178 | 0.63 | TAAR1 (0.37) | TAAR1KMT2AALDH1A1 | |
| SCHEMBL5215834 | 0.62 | KDM4E (0.42) | HTTRAB9ATAAR1KMT2AALDH1A1 | |
| SCHEMBL5216497 | 0.61 | CDK5 (0.42) | RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265138-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1818333-A1 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1603905-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004072068-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-20040157845-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157845-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885HTT 2205/4885RAB9A 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.